Twinbeech Capital LP lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 742.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 529,151 shares of the medical device company's stock after acquiring an additional 466,312 shares during the period. Twinbeech Capital LP owned 0.14% of DexCom worth $41,152,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of DXCM. Park Avenue Securities LLC lifted its holdings in DexCom by 13.9% in the 4th quarter. Park Avenue Securities LLC now owns 13,347 shares of the medical device company's stock valued at $1,038,000 after acquiring an additional 1,627 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in DexCom by 17.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 5,163 shares of the medical device company's stock valued at $402,000 after acquiring an additional 754 shares during the last quarter. Carnegie Investment Counsel lifted its holdings in DexCom by 11.0% in the 4th quarter. Carnegie Investment Counsel now owns 3,530 shares of the medical device company's stock valued at $275,000 after acquiring an additional 350 shares during the last quarter. Merit Financial Group LLC acquired a new stake in DexCom in the 4th quarter valued at about $228,000. Finally, UMB Bank n.a. lifted its holdings in DexCom by 82.4% in the 4th quarter. UMB Bank n.a. now owns 1,678 shares of the medical device company's stock valued at $130,000 after acquiring an additional 758 shares during the last quarter. Institutional investors own 97.75% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have commented on DXCM. Cfra Research raised shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Canaccord Genuity Group upped their price objective on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Morgan Stanley upped their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Piper Sandler reduced their price objective on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Finally, Citigroup reaffirmed a "buy" rating and set a $102.00 price objective (up from $82.00) on shares of DexCom in a research note on Thursday. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $98.00.
View Our Latest Report on DXCM
Insider Activity
In related news, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction on Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the sale, the executive vice president now directly owns 135,482 shares in the company, valued at approximately $10,002,636.06. This trade represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares in the company, valued at $26,183,401.02. This trade represents a 8.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,926 shares of company stock worth $4,734,384 over the last 90 days. 0.32% of the stock is currently owned by corporate insiders.
DexCom Trading Down 0.4%
Shares of DXCM stock traded down $0.32 on Friday, hitting $84.51. The company had a trading volume of 2,599,337 shares, compared to its average volume of 4,363,730. The firm has a market cap of $33.14 billion, a P/E ratio of 59.10, a P/E/G ratio of 2.30 and a beta of 1.43. The stock's 50-day moving average is $73.54 and its two-hundred day moving average is $78.13. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $128.63.
DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period in the prior year, the business earned $0.32 EPS. The company's revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.
DexCom Profile
(
Free Report)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Stories
Before you consider DexCom, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.
While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
